ArticleClinical kidney journal2026
Health-related quality of life in people with autosomal dominant polycystic kidney disease: a systematic review.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and a major contributor to kidney failure worldwide. However, the impact of ADPKD on health-related quality of life (HRQoL) across chronic kidney disease (CKD) stages and kidney replacement therapies (KRT) is poorly understood. This study aimed to synthesize existing evidence on HRQoL as measured by patient-reported outcome measures (PROMs) in people with ADPKD, stratified by disease stage and KRT modality. Methods: A systematic review was conducted using five databases (Medline, Embase, PsycINFO, CINAHL, Web of Science) and Google Scholar to identify studies published between January 2014 and October 2024. Eligible studies reported HRQoL in individuals with ADPKD using generic, kidney-specific, or ADPKD-specific PROMs Study populations were stratified by CKD stage and KRT modality. Scores were adjusted using country-specific population norms matched for age and sex, with population multipliers calculated to express patient-reported outcomes (PROs) as a proportion of the reference population. Results: Six studies assessed PROs using the Short-Form-36/12 survey. Physical health worsened with CKD progression, corresponding to lower values relative to matched population norms. Mental health showed smaller deviations from population norms. Dialysis patients had the lowest physical health multipliers, while transplant recipients had better physical health it did not improve to early-stage CKD levels. Two studies using the EuroQual 5-Dimension tool had fewer notable differences between CKD stages. Kidney disease and ADPKD-specific scores showed more pronounced declines across CKD stages than generic PROMs, suggesting greater sensitivity to stage-related changes. Conclusions: This review demonstrates that PROs for individuals with ADPKD are lower in later CKD stages compared with earlier stages, with the largest effect on physical health. Mental health scores were less affected suggesting adaptation over time. Our findings suggest generic PROMs may underestimate the impact of ADPKD compared to disease-specific tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.